||Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 556 active entries
1290 Terra Bella Ave
United States of America, California
Toll free: 8006622566
Takara Bio USA, Inc., (TBUSA; formerly Clontech Laboratories, Inc.) is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes life science research reagents, including SMARTer® cDNA synthesis kits (including a wide range of NGS kits); qPCR and PCR reagents; Tet-based inducible gene expression systems; and tools for genome editing and high-throughput protein purification. Under the Cellartis® brand, TBUSA offers cutting-edge stem cell products and services for drug discovery, toxicity testing, and applications within regenerative medicine. Takara Bio Inc. is a leading provider of equipment and reagents for biotechnology research, with particular strengths in PCR, enzyme systems, and protein expression, and also conducts research and development activities involving gene- and cell-based therapies and agricultural biotechnology. Together with its subsidiaries, Takara Bio Inc. is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.
Takara Bio USA, Inc., (formerly Clontech Laboratories, Inc.) is committed to developing innovative, high-performance tools to accelerate discovery. Through our Takara® and Clontech® brands, we offer high-quality PCR reagents for molecular diagnostic development and testing, and kits for demanding NGS applications such as low-input and single-cell RNA-seq from clinically relevant samples.
Takara Bio USA, Inc., (TBUSA; formerly Clontech Laboratories, Inc.) is committed to developing innovative, high-quality tools and services to accelerate discovery. Under the Cellartis® brand, TBUSA offers a broad range of iPS cells, highly functional human ES and iPS cell-derived hepatocytes and cardiomyocytes, and reagents for iPS cell culture and differentiation. We also provide services ranging from sourcing to generation to differentiation of custom cell lines.
Last update of this entry: July 12, 2017